National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.
Diabetes Obes Metab. 2024 Dec;26(12):5713-5726. doi: 10.1111/dom.15941. Epub 2024 Oct 2.
To assess the effects of vitamin D interventions on glycaemic control in subjects with type 2 diabetes (T2D).
We searched PubMed, EMBASE, Web of Science and the Cochrane Library for relevant studies. Serum 25(OH)D, fasting blood glucose (FBG), HbA1c, fasting insulin and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) were analysed.
We identified 39 randomized controlled trials involving 2982 subjects. Results showed a significant decline in the vitamin D group, as shown by the FBG weighted mean difference (WMD; -0.49 [95% confidence interval {CI}: -0.69 to -0.28] mmol/L), HbA1c (WMD -0.30% [95% CI: -0.43 to -0.18]), HOMA-IR (WMD -0.39 [95% CI -0.64 to -0.14]) and insulin (WMD -1.31 [95% CI: -2.06 to -0.56] μIU/mL). Subgroup analyses indicated that the effects of vitamin D supplementation on glycaemic control depend on the dosage and duration of supplementation, baseline 25(OH)D levels and the body mass index of patients with T2D.
Vitamin D supplementation can significantly reduce serum FBG, HbA1c, HOMA-IR and fasting insulin levels in T2D patients; the effects were especially prominent when vitamin D was given in a short-term, high dosage to patients with a vitamin D deficiency, who were overweight, or had an HbA1c of 8% or higher at baseline. Our study suggests that vitamin D supplements can be recommended as complementary treatment for T2D patients.
评估维生素 D 干预对 2 型糖尿病（T2D）患者血糖控制的影响。
我们检索了 PubMed、EMBASE、Web of Science 和 Cochrane 图书馆中相关的研究。分析了血清 25（OH）D、空腹血糖（FBG）、HbA1c、空腹胰岛素和胰岛素抵抗稳态模型评估（HOMA-IR）。
我们确定了 39 项随机对照试验，涉及 2982 名受试者。结果显示，维生素 D 组的 FBG 加权均数差值（WMD；-0.49mmol/L [95%置信区间 {CI}：-0.69 至 -0.28]）、HbA1c（WMD -0.30% [95% CI：-0.43 至 -0.18]）、HOMA-IR（WMD -0.39 [95% CI：-0.64 至 -0.14]）和胰岛素（WMD -1.31μIU/mL [95% CI：-2.06 至 -0.56]）均显著下降。亚组分析表明，维生素 D 补充对血糖控制的影响取决于补充剂量和持续时间、患者的基线 25（OH）D 水平和 T2D 患者的体重指数。
维生素 D 补充可显著降低 T2D 患者的血清 FBG、HbA1c、HOMA-IR 和空腹胰岛素水平；当维生素 D 缺乏、超重或基线 HbA1c 为 8%或更高的患者接受短期、高剂量维生素 D 治疗时，效果更为明显。我们的研究表明，维生素 D 补充剂可作为 T2D 患者的辅助治疗方法推荐。
